Karen S. Wright
Comptroller/Controller/Auditor bei STRUCTURE THERAPEUTICS INC.
Profil
Karen S.
Wright currently works at Structure Therapeutics, Inc., as Senior Vice President-Finance & Controller and Edge Ellison.
Ms. Wright also formerly worked at Cytokinetics, Inc., as Senior Director-Finance from 2001 to 2004, Elan Pharmaceuticals LLC, as Senior Director-Finance from 1997 to 2001, Genentech, Inc., as Senior Controller-Research & Development Group from 1984 to 1997, InterMune, Inc., as Vice President-Finance & Controller from 2004 to 2006, VIA Pharmaceuticals, Inc., as Vice President-Finance & Controller from 2006 to 2011, Veracyte, Inc., as Vice President-Finance & Controller from 2011 to 2014, Jaguar Animal Health, Inc., as Chief Financial Officer & Treasurer, VIA Pharmaceuticals, Inc., as Principal Financial Officer from 2010 to 2011, Clene Nanomedicine, Inc., as Head-Finance from 2014 to 2015, and Jaguar Health, Inc., as Treasurer, Chief Financial & Accounting Officer from 2015 to 2019.
Ms. Wright received her undergraduate degree from Haas School of Business.
Aktive Positionen von Karen S. Wright
| Unternehmen | Position | Beginn |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Comptroller/Controller/Auditor | - |
Ehemalige bekannte Positionen von Karen S. Wright
| Unternehmen | Position | Ende |
|---|---|---|
| JAGUAR HEALTH, INC. | Finanzdirektor/CFO | 09.08.2019 |
Clene Nanomedicine, Inc.
 Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | Finanzdirektor/CFO | 01.11.2015 |
| VERACYTE, INC. | Comptroller/Controller/Auditor | 01.05.2014 |
| VIA PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 01.03.2011 |
VIA Pharmaceuticals, Inc. /Old/
 VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 01.01.2011 |
Ausbildung von Karen S. Wright
| Haas School of Business | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| VIA PHARMACEUTICALS, INC. | Health Technology |
| CYTOKINETICS, INCORPORATED | Health Technology |
| VERACYTE, INC. | Health Technology |
| JAGUAR HEALTH, INC. | Health Technology |
| STRUCTURE THERAPEUTICS INC. | Commercial Services |
| Private Unternehmen | 6 |
|---|---|
VIA Pharmaceuticals, Inc. /Old/
VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Elan Pharmaceuticals, LLC
 Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Jaguar Animal Health, Inc.
 Jaguar Animal Health, Inc. Pharmaceuticals: MajorHealth Technology Jaguar Animal Health, Inc. engages in the development and commercialization of gastrointestinal products for companion and production animals. Its product, Canalevia, is the company's prescription drug product candidate for the treatment of various forms diarrhea in dogs. It also developed its non-prescription product, Neonorm Calf, which helps dairies and beef farms proactively retain fluid in calves. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | Health Technology |
